Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsPCR-negative conversion
chloroquine and derivatives6- 1.36 [0.87; 2.11], 1 RCT, I2=0%
inconclusive result
1.06 [0.21; 5.31], 5 RCTs, I2=0%
inconclusive result
0.93 [0.62; 1.40], 2 RCTs, I2=0%
inconclusive result
ivermectin4--- 0.92 [0.77; 1.09], 2 RCTs, I2=0%
inconclusive result
azithromycin1--- OBS 715.00 [12.94; 39513.71], 1 study, I2=0%
unassessable degree of certainty
doxycycline1----
fluvoxamine1 0.07 [0.00; 1.26], 1 RCT, I2=0% demonstrated
inconclusive result
---
hydroxychloroquine plus macrolides1--- 0.64 [0.42; 0.98], 2 RCTs, I2=0%
statistically significant harm
ASC09/ritonavir0----
azvudine0----
baloxavir marboxil0----
carrimycin0----
danoprevir / ritonavir0----
darunavir cobicistat0----
darunavir/cobicistat plus chloroquine0----
favipiravir 0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir0----
lopinavir/ritonavir plus chloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
lopinavir/ritonavir, ribavirin and interferon beta-1b0----
meplazumab0----
nitazoxanide0----
oseltamivir0----
oseltamivir plus chloroquin0----
remdesivir0----
Renin-angiotensin-system-acting agents0----
ribavirin0----
ritonavir0----
sofosbuvir and daclatasvir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
triazavirin0----
umifenovir (arbidol)0----